Sahni J, Dugel PU, Patel SS, et al. - Researchers conducted this phase 2 randomized clinical trial (AVENUE) to test the safety and effectiveness of different doses and regimens of faricimab vs ranibizumab in patients with neovascular age-related macular degeneration (nAMD). Eligible candidates were anti-VEGF treatment naive with choroidal neovascularization secondary to nAMD and best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 73 (Snellen equivalent, 20/40) to 24 (Snellen equivalent, 20/320). In total, 263 participants were involved in the analysis (172 [65.4%] female; 258 [98.1%] white; mean [SD] age, 78.3 [8.7] years). At week 36, AVENUE did not reach its primary endpoint of faricimab dominance over ranibizumab in BCVA. While not superior to the monthly ranibizumab given in this study, the overall visual and anatomical improvements with faricimab support for phase 3 trials have been noted as a possible alternative to monthly anti-VEGF therapy. Faricimab has shown no new or unexpected safety signals.